A study has found that an investigational daily pill can double survival in patients with metastatic pancreatic cancer. The pill, which is a RAS inhibitor, has shown promising results in extending survival, with some reports indicating it also reduces side effects. The drug's effectiveness has been described as a significant breakthrough, with potential for use in other applications beyond pancreatic cancer.